Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer.

ABSTRACT: A design is presented for a randomized clinical trial comparing two second-line treatments, chemotherapy versus chemotherapy plus reirradiation, for treatment of recurrent non-small-cell lung cancer. The central research question is whether the potential efficacy benefit that adding reirradiation to chemotherapy may provide justifies its potential for increasing the risk of toxicity. The design uses two co-primary outcomes: time to disease progression or death, and time to severe toxicity. Because patients may be given an active third-line treatment at disease progression that confounds second-line treatment effects on toxicity and survival following disease progression, for the purpose of this comparative study follow-up ends at disease progression or death. In contrast, follow-up for dis

SUBMITTER: Murray TA 

PROVIDER: S-EPMC5607962 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature